{"doi":"10.1158/1055-9965.c.6516087","title":"Data from Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men","abstract":"&lt;div&gt;Abstract&lt;p&gt;&lt;b&gt;Background:&lt;/b&gt; Men of African descent experience a disproportionately high prostate cancer mortality. Intratumoral inflammation was found to be associated with aggressive prostate cancer. We and others have shown that prostate tumors in African-American (AA) patients harbor a distinct immune and inflammation signature when compared with European-American (EA) patients. These observations suggest that inflammation could be a driver of aggressive disease in men of African descent, leading to the hypothesis that an anti-inflammatory drug like aspirin could prevent disease progression.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; We examined the relationship between aspirin use and prostate cancer in the NCI-Maryland Prostate Cancer Case-Control Study consisting of 823 men with incident prostate cancer (422 AA and 401 EA) and 1,034 population-based men without the disease diagnosis (486 AA and 548 EA).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; We observed a significant inverse association between regular aspirin use and prostate cancer among AA men. Stratification of AA patients by disease stage showed that daily and long-term (&gt;3 years) aspirin use significantly decreased the risk of advanced disease [adjusted ORs for T3/T4 disease: 0.35, 95% confidence interval (CI), 0.17–0.73; and 0.22, 95% CI, 0.08–0.60, respectively], but not early-stage disease (T1/T2). Regular aspirin use also reduced disease recurrence in AA men.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; Regular aspirin use is associated with a decreased risk of advanced stage prostate cancer and increased disease-free survival in AA men.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Impact:&lt;/b&gt; Regular aspirin use before and after a prostate cancer diagnosis may prevent the development of aggressive disease in AA men who are at risk of a lethal malignancy. &lt;i&gt;Cancer Epidemiol Biomarkers Prev; 26(6); 845–53. ©2017 AACR&lt;/i&gt;.&lt;/p&gt;&lt;/div&gt;","journal":null,"year":2023,"id":405076,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9589,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":210848,"name":"Tiffany H. Dorsey","orcid":"0009-0003-1334-0098","position":1,"is_corresponding":false},{"id":7756,"name":"Wei Tang","orcid":"0000-0002-2662-217X","position":2,"is_corresponding":false},{"id":821844,"name":"Symone V. Jordan","orcid":null,"position":3,"is_corresponding":false},{"id":474640,"name":"Christopher A. Loffredo","orcid":"0000-0002-3134-6894","position":4,"is_corresponding":false},{"id":130771,"name":"Stefan Ambs","orcid":"0000-0001-7651-9309","position":5,"is_corresponding":false},{"id":626723,"name":"Cheryl J. Smith","orcid":null,"position":0,"is_corresponding":true}],"reference_count":52,"raw_metadata":null,"created_at":"2026-07-19T01:20:49.237119Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}